Asset Management Group, Inc. Abb Vie Inc. Transaction History

Asset Management Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $535,204 - $669,655	-7,420 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $164,566 - $197,856	-2,613 Reduced 26.04%	7,420 $562,000
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $2,693 - $3,443	41 Added 0.41%	10,033 $730,000
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $1,234 - $1,452	16 Added 0.16%	9,992 $805,000
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $934 - $1,152	12 Added 0.12%	9,976 $920,000
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $1,066 - $1,186	12 Added 0.12%	9,964 $942,000
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $897 - $1,062	10 Added 0.1%	9,952 $922,000
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $644 - $862	7 Added 0.07%	9,942 $941,000
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $716 - $785	8 Added 0.08%	9,935 $961,000
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $693,400 - $885,686	9,927	9,927 $882,000

3,848

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Asset Management Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Asset Management Group, Inc. with notifications on news.